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Abstract
Background: There is anatomical and behavioural evidence that μ-a n dδ-opioid receptors modulate distinct
nociceptive modalities within the superficial dorsal horn. The aim of the present study was to examine whether μ-a n d
δ-opioid receptor activation differentially modulates TRP sensitive inputs to neurons within the superficial dorsal horn.
To do this, whole cell patch clamp recordings were made from lamina I - II neurons in rat spinal cord slices in vitro to
examine the effect of opioids on TRP agonist-enhanced glutamatergic spontaneous miniature excitatory postsynaptic
currents (EPSCs).
Results: Under basal conditions the μ-opioid agonist DAMGO (3 μM) reduced the rate of miniature EPSCs in 68%
of neurons, while the δ- and -opioid agonists deltorphin-II (300 nM) and U69593 (300 nM) did so in 13 - 17% of
neurons tested. The TRP agonists menthol (400 μM) and icilin (100 μM) both produced a Ca
2+-dependent increase
in miniature EPSC rate which was unaffected by the voltage dependent calcium channel (VDCC) blocker Cd
2+. The
proportion of neurons in which deltorphin-II reduced the miniature EPSC rate was enhanced in the presence of
icilin (83%), but not menthol (0%). By contrast, the proportion of DAMGO and U69593 responders was unaltered in
the presence of menthol (57%, 0%), or icilin (57%, 17%).
Conclusions: These findings demonstrate that δ-opioid receptor activation selectively inhibits inputs activated by
icilin, whereas μ-opioid receptor activation has a more widespread effect on synaptic inputs to neurons in the
superficial dorsal horn. These findings suggest that δ-opioids may provide a novel analgesic approach for specific,
TRPA1-like mediated pain modalities.
Background
The superficial dorsal horn of the spinal cord is a major
site of μ-opioid receptor mediated analgesia [1]. There is
some evidence that spinally delivered δ-opioid agonists
also inhibit behavioural responses to a range of noxious
stimuli [2-9]. It has been suggested, however, that
μ-opioid receptors mediate the analgesic actions of
δ-opioid agonists, particularly at high doses [e.g.
[10,11]]. Alternatively, the variability in the analgesic
efficacy of spinally delivered δ-opioid agonists might be
due to the use of different pain assays in these studies
[12,13]. In this regard, it has recently been demonstrated
that noxious thermal and mechanical pain are mediated
by distinct primary afferents and spinal pathways,
and that these pathways are differentially modulated by
μ- and δ-opioid receptors [13,14].
Opioids are thought to produce their effects within
the dorsal horn by inhibiting neurotransmitter release
from the central terminals of primary afferent nocicep-
tors, and by postsynaptic inhibition of dorsal horn neu-
rons [1]. A number of in vitro studies have reported
that μ-opioid receptor agonists presynaptically inhibit
glutamatergic synaptic transmission onto subpopulations
of lumbar and trigeminal dorsal horn neurons [15-21].
In these studies μ- o p i o i d si n h i b i ta f f e r e n te v o k e dg l u t a -
matergic excitatory postsynaptic currents (EPSCs) and
reduce the rate of spontaneous miniature EPSCs. By
contrast, there are mixed reports on δ-opioid receptor
agonists, with some studies demonstrating inhibition of
glutamatergic synaptic transmission in dorsal horn
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little, or no effect [15,17,19].
The examination of opioid actions on specific nocicep-
tive afferent inputs to dorsal horn neurons is limited with
the in vitro approach because of the inability to naturally
activate different afferent modalities, although this may
be overcome with the in vivo patch clamping approach
[22-24]. The transport of a range of proteins, including
transient receptor potential (TRP) ion channels, to the
central terminals of primary afferent fibres provides a
means to pharmacologically differentiate between subpo-
pulations of nociceptive afferent inputs to dorsal horn
neurons in an in vitro preparation. This approach has
been used previously to differentiate TRPV1, TRPM8
and TRPA1 sensitive inputs to dorsal horn neurons in
intact spinal cord slices [25-32]. In these studies, TRP-
mediated presynaptic enhancement of glutamatergic
synaptic transmission is observed as an increase in minia-
ture EPSC rate, although, TRP agonists produce a para-
doxical decrease in afferent evoked EPSCs [but see [33]].
I nt h ep r e s e n ts t u d yw eu s e da nin vitro approach to
examine whether different opioid receptor subtypes mod-
ulate specific TRP-sensitive inputs to neurons within the
superficial dorsal horn by examining their opposing
effects on spontaneous miniature EPSCs.
Methods
Animals
Experiments were carried out on male Sprague-Dawley
rats (14 - 21 days old), following the guidelines of the
‘NH&MRC Code of Practice for the Care and Use of Ani-
mals in Research in Australia’ and with the approval of
the Royal North Shore Hospital Animal Care and Ethics
Committee. Animals were anaesthetized with halothane
(1 - 3% in O2) and a laminectomy was performed to
expose the lumbar spinal cord. The dura was incised and
the spinal column quickly removed and placed in ice
cold artificial cerebrospinal fluid (ACSF) of composition:
( m M ) :N a C l ,1 2 6 ;K C l ,2 . 5 ;N a H 2PO4,1 . 4 ;M g C l 2,1 . 2 ;
CaCl2,2 . 4 ;g l u c o s e ,1 1 ;N a H C O 3,2 5 .T h ea n i m a lw a s
then euthanased by decapitation. Transverse (300 μm)
slices of the lumbar spinal cord (L4 - 6) were cut and
maintained at room temperature in a submerged cham-
ber containing ACSF equilibrated with 95% O2 and 5%
CO2. The slices were then transferred to a chamber and
superfused continuously (1.8 ml.min
-1)w i t hA C S Fa t3 4 °
C using an in-line temperature controller (CL-100, War-
ner Instruments, Hampden, USA). In some experiments
ACSF was modified. NaH2PO4 was omitted in Cd
2+
experiments; Mg
2+ was increased to 10 mM in Ca
2+-free
experiments; NaCl was reduced to 103.5 mM in high K
+
(KCl 25 mM) experiments. In these cases, the altered
ACSF was superfused onto the slice for at least 30 min
before recordings were commenced.
Electrophysiology
Dorsal horn neurons were visualized using infra-red
Nomarski, or Dodt-tube optics on an upright microscope
(Olympus BX50, Olympus, Sydney, Australia). Whole-
cell voltage clamp recordings (holding potential -65 mV,
liquid junction potential corrected) were made using an
Axopatch 200B amplifier (Molecular Devices, Sunnyvale,
CA, USA) with patch clamp electrodes (2 - 5 MΩ). The
internal solution contained (mM): CsMeSO3 135, EGTA
10, HEPES 5, NaCl 10, MgCl2 1 and MgATP 2. All inter-
nal solutions were adjusted to pH 7.3 and osmolality
2 8 0-2 8 5m o s m o l . l
-1. Series resistance (< 25 MΩ)w a s
compensated by 80% and continuously monitored during
experiments.
Spontaneous miniature EPSCs were recorded in the
presence of tetrodotoxin (TTX, 500 nM), the GABAA
channel blocker picrotoxin (100 μM) and the glycine
receptor antagonist strychnine (3 μM). EPSCs were fil-
tered (2 kHz low-pass filter) and sampled (10 kHz) in 4
second epochs every 6 seconds for analysis using Axo-
graphX (Axograph Scientific, Sydney, Australia). For ana-
lysis, miniature EPSCs above a preset threshold (4.0 - 4.5
standard deviations above baseline noise) were automati-
cally detected by a sliding template algorithm and then
manually checked. We did not exclude, or separate
merged EPSCs (with < 5 ms inter-event interval separa-
tion) which sometimes occurred at high EPSC rates and
led to an increase in the mean EPSC amplitude. Neurons
were considered to be opioid responders if there was a
decrease in miniature EPSC rate which was greater than
15% and returned to baseline after washout, or addition
of an antagonist.
Chemicals and statistical analysis
Allyl-isothiocyanate, CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-
Pen-Thr-NH2), DAMGO (Tyr-D-Ala-Gly-N-Me-Phe-Gly-
ol enkephalin), deltorphin-II, (1R,2S,5R)-(-)-menthol,
picrotoxin, strychnine hydrochloride and U69593 were
obtained from Sigma (Sydney, Australia); icilin (3,6-
dihyrdo-1-(2-hydroxyphenyl)-4-(3-nitrophenyl)-2(1H)-
pyrimidinone) was from Cayman Chemical Co. (Ann
Arbor, U.S.A.); (E)-capsaicin, CNQX (6-cyano-7-nitroqui-
noxaline-2,3-dione disodium), ICI-174,864, naloxone and
nor-BNI (nor-binaltorphimine dihydrochloride) were from
Tocris Cookson (Bristol, U.K.); QX 314 and TTX (tetrodo-
toxin) were from Alomone (Jerusalem, Israel). Stock solu-
tions of all drugs were made in distilled water, except
U69593 (in 0.1 M HCl), icilin (in dimethylsulfoxide), cap-
saicin and menthol (in ethanol). These were diluted to
working concentrations using ACSF immediately before
use, except for picrotoxin which was dissolved directly
into ACSF, and were applied by superfusion. The order
in which opioid agonists were applied was randomised.
All statistical comparisons were made using one- and
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un-paired t-tests. All pooled data are expressed as mean ±
S.E.M.
Results
Opioid inhibition of miniature EPSCs under basal
conditions is largely mediated by μ-opioid receptors
We first examined the effect of μ-, δ- and -opioid recep-
tor activation on miniature EPSCs in lamina I - II neu-
rons of the dorsal horn under basal conditions. In the
presence of TTX (500 nM), picrotoxin (100 μM) and
strychnine (3 μM), superfusion of the μ-opioid receptor
agonist DAMGO (3 μM) produced a decrease in the rate
of miniature EPSCs in 68% (n = 15/22) of neurons tested
(Figure 1a, c, 2b). In the responding neurons, the minia-
ture EPSC rate during superfusion of DAMGO was 51 ±
5% of the pre-opioid level (n = 15). When averaged
across all neurons, the miniature EPSC rate during super-
fusion of DAMGO was 68 ± 8% of the pre-opioid level
(Figure 2a, p = 0.0005, n = 22). The decrease in miniature
EPSC rate produced by DAMGO was reversed by the
addition of the μ-opioid receptor antagonist CTAP
(1 μM, n = 3), or the non-selective opioid receptor nalox-
one (1 μM, n = 10) which was in some cases associated
with rebound facilitation (Figure 1a, c). The decrease
i nm i n i a t u r eE P S Cr a t ep r o d u c e db yD A M G Ow a s
associated with a rightward shift in the cumulative prob-
ability distributions of miniature EPSC inter-event inter-
vals (Figure 1d). DAMGO had no effect on the kinetics
and amplitude of miniature EPSCs, or on the cumulative
probability distributions of miniature EPSC amplitudes
(Figure 1b, e).
The δ-opioid receptor agonist deltorphin-II (300 nM)
had no effect on miniature EPSCs in most neurons
(Figure 1). Deltorphin II reduced the rate of miniature
EPSCs in only 13% (n = 2/15) of neurons tested (Figure
2b; 47 and 79% of pre-opioid level in the responders).
When averaged across all neurons, the miniature EPSC
rate during superfusion of deltorphin-II was 95 ± 6% of
the pre-opioid level (Figure 2a, p = 0.4, n = 15). In the
deltorphin-II responding neurons, the decrease in minia-
ture EPSC rate was reversed by the addition of the
δ-opioid receptor antagonist ICI-174864 (1 μM, n = 2).
It might be noted however that a higher concentration
of deltorphin (10 μM) produced a decrease in miniature
EPSC rate in 71% of neurons tested (n = 5/7), which
was significant when averaged across all neurons (78 ±
7% of the pre-opioid level, p = 0.02, n = 7). This high
concentration deltorphin-II (10 µM) induced inhibition
was reversed by addition of ICI-174864 (1 μM) in only
one neuron and was reversed by addition of CTAP
(1 μM) in the other four neurons. Deltorphin-II, at both
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Figure 1 μ-Opioids presynaptically inhibit basal glutamatergic transmission in superficial dorsal horn neurons. (a) Time plot of miniature
EPSC (mEPSC) rate during superfusion of deltorphin-II (Delt, 300 nM), DAMGO (3 μM) and naloxone (Nalx, 1 μM). (b) Averaged traces and (c) raw
current traces of mEPSCs prior to (Pre), and during deltorphin-II, DAMGO and naloxone. Cumulative probability distribution plots of mEPSC (d)
inter-event interval and (e) amplitude for the epochs averaged in (b) (number of events = 635, 640, 327 for control, deltorphin-II and DAMGO,
respectively, over 80 s intervals). (a) - (e) are taken from one neuron.
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tude of miniature EPSCs, or on the cumulative probabil-
ity distributions of miniature EPSC amplitudes (Figure
1b, e).
Finally, the -opioid receptor agonist U69593 (300 nM)
reduced the miniature EPSC rate in only 17% (n = 2/12)
of neurons tested (Figure 2b; 50 and 75% of pre-opioid
level in the two responders). When averaged across all
neurons, the miniature EPSC rate during superfusion of
U69593 was 98 ± 6% of the pre-opioid levels (Figure 2a,
p = 0.7, n = 12). In the U69593 responding neurons, the
decrease in miniature EPSC rate was reversed by the addi-
tion of the -opioid receptor antagonist nor-BNI (300 nM,
n = 2). U69593 had no effect on the kinetics and ampli-
tude of miniature EPSCs, or on the cumulative probability
distributions of miniature EPSC amplitudes. Overall, these
observations suggest that μ-opioid receptor activation pre-
synaptically inhibits basal glutamatergic synaptic transmis-
sion in a much larger subpopulation of superficial dorsal
horn neurons, than δ-, or -opioid receptor activation.
Opioid inhibition of miniature EPSCs is unaffected by
menthol
Superfusion of menthol (400 μM) produced an increase in
miniature EPSC rate in 86% of neurons tested (Figure 3a,
c, n = 12/14). On average the miniature EPSC rate was 7.9
±1 . 8s
-1 and 25.3 ± 3.4 s
-1 prior to, and during application
of menthol (p = 0.002, n = 14). The increase in miniature
EPSC rate produced by menthol was associated with a left-
ward shift in the cumulative probability distribution of the
miniature EPSC inter-event intervals (Figure 3d). In many
of the responding neurons (n = 8/12), menthol also pro-
duced an increase in the amplitude of miniature EPSCs
which was due to summation of individual events during
burst-like activity (Figure 3b, c, 133 ± 9% of pre-menthol,
p = 0.005, n = 14).
We next examined the actions of opioids in neurons
which responded to menthol with an increase in minia-
ture EPSC rate. In the presence of menthol (400 μM),
DAMGO (3 μM) produced a decrease in the rate of min-
iature EPSCs in 57% (n = 4/7) of neurons tested which
was reversed by the addition of CTAP (1 μM, n = 2), or
naloxone (1 μM, n = 2) (Figure 2b, 3a, c). Under these
conditions, the miniature EPSC rate during superfusion
of DAMGO in the responding neurons was 45 ± 9% of
pre-opioid levels (n = 4). By contrast, deltorphin-II (300
nM, n = 6) and U69593 (300 nM, n = 6) did not produce
a decrease in the rate of miniature EPSCs in any neurons
tested in the presence of menthol (Figure 2b, 3a, c).
When averaged across all neurons, the miniature EPSC
rate during superfusion of DAMGO, deltorphin-II and
U69593 was 67 ± 11% (n = 7), 97 ± 1% (n = 6) and 103 ±
3% (n = 6) of pre-opioid levels, respectively (Figure 2a,
p = 0.03, 0.1, 0.4). DAMGO, but not deltorphin-II and
U69593 produced a rightward shift in the cumulative
probability distribution of the miniature EPSC inter-
event intervals (Figure 3d). On average, DAMGO, deltor-
phin-II and U69593 had no effect on the kinetics and
amplitude of miniature EPSCs, or on the cumulative
probability distributions of miniature EPSC amplitudes in
the presence of menthol (Figure 3b, e).
High micromolar icilin increases the incidence of δ-opioid
inhibition of miniature EPSCs
Superfusion of icilin (100 μM) produced an increase in
miniature EPSC rate in 79% of neurons tested (Figure 4a,
c, n = 11/14). On average the miniature EPSC rate was
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Figure 2 Effect of opioids on basal, and menthol and icilin
enhanced miniature EPSCs. (a) Bar chart showing the percentage
inhibition of miniature EPSC (mEPSC) rate produced by DAMGO (3
μM), deltorphin-II (Delt, 300 nM) and U69593 (300 nM), expressed as
a percentage of the pre-opioid level and averaged across all
neurons tested. (b) Bar chart showing the percentage of neurons in
which DAMGO, deltorphin-II and U69593 produced a reduction in
mEPSC rate of greater than 15%. Data in (a) and (b) are shown for
neurons in which opioids were superfused alone, or in the
additional presence of menthol (400 μM), or icilin (100 μM). The
number in the bars represent (a) the total number of neurons
tested and (b) the number of neurons which responded to each
opioid.
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Page 4 of 105.6 ± 0.5 s
-1 a n d1 9 . 9±2 . 7s
-1 prior to, and during appli-
cation of icilin (p = 0.0004, n = 14). The increase in min-
iature EPSC rate produced by icilin was associated with a
leftward shift in the cumulative probability distribution
of the miniature EPSC inter-event intervals (Figure 4d).
In some of the responding neurons (n = 4/11), icilin also
produced an increase in the amplitude of miniature
EPSCs which was due to summation of individual events
during burst-like activity (128 ± 9% of pre-icilin, p = 0.01,
n = 11).
We next examined the actions of opioids in neurons
which responded to icilin with an increase in miniature
EPSC rate. In the presence of icilin (100 μM), DAMGO
(3 μM) and deltorphin-II (300 nM) produced a decrease
in the rate of miniature EPSCs in 57% (n = 4/7) and
83% (n = 5/6) of neurons tested (Figure 2b, 4a, c). By
contrast, U69593 (300 nM) produced a decrease in the
rate of miniature EPSCs in only 17% (n = 1/6) of neu-
rons tested in the presence of icilin (Figure 2b, 4a, c).
Under these conditions, the miniature EPSC rate during
superfusion of DAMGO, deltorphin-II and U69593 in
the responding neurons was 44 ± 9%, 74 ± 2% and 47%
of pre-opioid levels, respectively (n = 4, 7, 1). When
averaged across all neurons, the average miniature EPSC
rate during superfusion of DAMGO, deltorphin-II and
U69593 was 69 ± 12%, 76 ± 3% and 97 ± 10% of pre-
opioid levels, respectively (Figure 2a, p = 0.04, 0.0003,
0.8, n = 7, 6, 6). The decrease in miniature EPSC rate
produced by DAMGO, deltorphin-II and U69593 was
reversed by the addition of CTAP (1 μM, n = 4), ICI-
174864 (1 μM, n = 5) and nor-BNI (300 nM, n = 1),
respectively (Figure 4a). The decrease in miniature
EPSC rate produced by DAMGO, deltorphin-II and
U69593 was associated with a rightward shift in the
cumulative probability distribution of the miniature
EPSC inter-event intervals (Figure 4d). On average,
DAMGO, deltorphin-II and U69593 had no effect on
the kinetics and amplitude of miniature EPSCs, or on
the cumulative probability distributions of miniature
EPSC amplitudes in the presence of icilin (Figure 4b, e).
Role of presynaptic calcium
We next examined whether the difference in δ-opioid
modulation of menthol and icilin enhanced synaptic
transmission was related to presynaptic calcium mechan-
isms. To do this, we compared the increase in miniature
EPSC rate produced by icilin and menthol under control
conditions (normal ACSF), to that in the presence of the
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Page 5 of 10voltage dependent calcium channel (VDCC) blocker Cd
2+
(30 μM), or in the absence of external Ca
2+.T h eb a s a l
miniature EPSC rate was less in the presence of Cd
2+
(1.7 ± 0.4 s
-1,p<0 . 0 0 1 ,n=1 6 )a n di nt h ea b s e n c eo f
external Ca
2+ (3.3 ± 0.5 s
-1, p < 0.01, n = 21), compared
to that in normal ACSF (6.6 ± 0.9 s
-1,n=3 8 ) .T h eb a s a l
miniature EPSC amplitude was similar in the presence of
Cd
2+, in the absence of external Ca
2+ and in normal
ACSF (32 ± 4 pA, 31 ± 2 pA and 28 ± 2 pA, p = 0.3).
I nt h ep r e s e n c eo fC d
2+ (30 μM), menthol (400 μM)
produced an increase in the rate of miniature EPSCs (p =
0.009, n = 7) which was not significantly different to that
produced in normal ACSF (n = 14) (Figure 5, p = 0.07).
Icilin (100 μM) also produced an increase in the rate of
miniature EPSCs in the presence of Cd
2+ (p = 0.03, n =
6) which was not significantly different to that produced
in its absence (n = 14) (Figure 5, p = 0.1). By contrast,
menthol and icilin did not produce a significant increase
in miniature EPSC rate in the absence of external Ca
2
+(Figure 5, p = 0.09, 0.6, n = 7, 7). As a control we also
examined whether raising the external concentration of
potassium produced a calcium dependent increase in
miniature EPSC rate. In all neurons tested, increasing
external potassium ([K
+]ext = 25 mM) produced an
increase in the rate of miniature EPSCs in normal ACSF
(p = 0.04, n = 4), but not in the presence of Cd
2+ (30 μM,
p = 0.8, n = 4), or in the absence of external Ca
2+(p = 0.9,
n = 4) (Figure 5).
Discussion
The present findings suggest that δ-opioids presynapti-
cally inhibit a distinct subpopulation of glutamatergic
inputs onto dorsal horn neurons which are activated by
the TRP agonist icilin. By contrast, activation of presy-
naptic μ-opioid receptors inhibits multiple types of
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findings provide cellular evidence that μ-a n dδ-opioid
receptors are expressed by partially distinct inputs to
dorsal horn neurons and potentially subserve different
pain modalities.
In the present study the inhibition of glutamatergic
synaptic transmission produced by low micromolar con-
centrations of DAMGO, deltorphin-II and U69593 was
mediated via μ-, δ-a n d-opioid receptors. This inhibition
was likely to be presynaptic because opioids produced a
reduction in the rate of asynchronous spontaneous minia-
ture EPSCs, without any change in their amplitude, or
kinetics. Our findings are largely consistent with previous
reports of μ-opioid receptor mediated presynaptic inhibi-
tion of glutamatergic synaptic transmission in the majority
of lamina I - II superficial dorsal horn neurons under basal
conditions [15-20]. The low incidence of δ- and -opioid
receptor mediated inhibition reflects the mixed findings of
previous studies, in which δ-a n d-opioid agonists have
been reported to either inhibit, or have little, or no effect
on glutamatergic synaptic transmission in dorsal horn
neurons [15,17-20,34,35]. The differences in the propor-
tions of opioid responders between these studies may have
been due to the use of different response criterion (e.g.
responders if inhibition > 15% in the present study versus
5% in Kohno et al. [20]). The differences may have also
been due to the use of high agonist concentrations in
some in vivo and in vitro studies [17,18,21,34] and the pos-
sible involvement of μ-opioid receptors in the actions of
δ-opioid agonists [e.g. [11]]. Indeed, we found that higher
concentrations of deltorphin-II (10 μM) produced both
μ- and δ-opioid receptor mediated presynaptic inhibition.
It is also possible that these differences were due to varia-
tions in presynaptic excitability, VDCCs and intracellular
calcium buffering (see below).
The enhancement of glutamatergic synaptic transmis-
sion by menthol and icilin was likely to be due to a presy-
naptic action because they produced an increase in the
rate of miniature EPSCs, as shown previously for a range
of TRP agonists [25-29,31-33]. The presynaptic actions of
menthol and icilin are partly consistent with activation of
TRPM8 and TRPA1, respectively [36-38]. While menthol
is typically used as a TRPM8 agonist, it has also been
reported to be a ligand at TRPA1 and TRPV3 ion channels
[39,40]. In addition, icilin activates TRPM8 and TRPA1 at
low and high micromolar concentrations, respectively
[32,36,38]. The actions of high micromolar icilin in the
present study are more consistent with TRPA1 activation
because the enhancement of spinal glutamatergic synaptic
transmission by high micromolar icilin is highly correlated
to that produced by activation of TRPA1, but not TRPM8
[[29], see also [32]]. We did not confirm the identity of the
TRP channels with other TRPA1 agonists, such as allyl-
isothiocyanate and cinnamaldehyde, because they produce
rapidly desensitising increases in miniature EPSC rate [29]
that precluded subsequent examination of opioid inhibi-
tion. Thus, the precise role of TRPM8 and TRPA1 in
the presynaptic enhancement of synaptic transmission
produced by both menthol and icilin remains to be
confirmed.
The menthol and icilin induced enhancement of synap-
tic transmission and the subsequent opioid inhibition
were likely to be due to an action on the terminals of pri-
mary afferents, as opposed to the terminals of spinal
interneurons, or descending medullo-spinal fibres. There
is anatomical evidence that TRPM8 and TRPA1 are
expressed exclusively by dorsal root ganglion (DRG) neu-
rons and their central terminals [36-38,41]. In addition,
slice studies have shown that, like capsaicin, menthol, ici-
lin and cinnamaldehyde inhibit dorsal root evoked
EPSCs, with TRPA1 agonists specifically inhibiting
C-fibre evoked EPSCs [[29-31], but see [33]]. This para-
doxical TRP induced inhibition of evoked EPSCs pre-
cluded the examination of opioid inhibition of menthol
and icilin sensitive primary afferent evoked EPSCs. As a
result, in the present study miniature EPSCs, rather than
primary afferent evoked EPSCs were examined.
μ-Opioid receptor activation inhibited basal, and
menthol/icilin-enhanced glutamatergic synaptic transmis-
sion in 57 - 68% of neurons tested. By contrast, δ-opioid
receptor activation inhibited icilin-enhanced glutamatergic
synaptic transmission in virtually all neurons tested, but
had little effect on basal and menthol-enhanced glutama-
tergic synaptic transmission. The difference in μ-a n d
δ-opioid inhibition may have been due to variations in
presynaptic opioid signalling. It has previously been
reported that μ-opioid inhibition of miniature EPSCs in
lamina I is mediated by presynaptic VDCCs [15]. While
μ-opioid receptor activation inhibits VDCCs in subpopula-
tions of DRG neurons, the observation of δ- and -opioid
inhibition varies between studies [21,42-46]. We found
that the increase in miniature EPSC rate produced by both
menthol and icilin was dependent upon external calcium,
but was unaffected by presynaptic VDCC blockade, as
observed previously for menthol, allyl-isothiocyanate and
cinnamaldehyde [28,31,33]. The μ-a n dδ-opioid inhibition
observed in the presence of menthol and icilin was there-
fore not likely to be mediated by presynaptic VDCCs and
cannot account for the observed differences. The depen-
dence upon external calcium is consistent with the finding
that TRPM8 enhancement of synaptic transmission is
mediated by release of calcium from intracellular stores
within afferent nerve terminals [33]. While it is interesting
to note that intracellular calcium regulation varies between
different types of DRG neurons [47], there are few reports
of opioid regulation of intracellular calcium [48,49]. The
Wrigley et al. Molecular Pain 2010, 6:71
http://www.molecularpain.com/content/6/1/71
Page 7 of 10precise mechanisms underlying opioid modulation of
TRPM8 and TRPA1 enhanced synaptic transmission
therefore remain to be determined.
T h ed i f f e r e n c ei nμ-a n dδ-opioid inhibition may also
have been due to δ-opioid receptor translocation. There
is evidence to suggest that unlike μ-opioid receptors,
δ-opioid receptors are largely located in intracellular
compartments of nerve terminals in DRG neurons and
the dorsal horn under normal conditions [50-54]. Sti-
muli, such as depolarisation, swim-stress, inflammation,
chronic morphine treatment, TRPV1 and δ-opioid
receptor activation, induce translocation of δ-opioid
receptors to the surface membrane within DRG neu-
rons, the dorsal horn and brain [49,54-58]. In this
regard, electrophysiological studies have reported de
novo δ-opioid inhibition of synaptic transmission in des-
cending analgesic pathways following chronic morphine
treatment [59-62]. Simple activity-dependent receptor
externalisation, however, does not readily explain the
increased δ-opioid sensitivity observed in the presence
of icilin because similar increases in miniature EPSC
rate were seen with both menthol and icilin.
The most likely explanation for the observed differen-
tial opioid inhibition is that δ-opioids act on a distinct
subpopulation of afferent nerve terminals within the
superficial dorsal horn which express TRPA1-like ion
channels. Anatomical studies have shown that TRP chan-
nel expression in DRG neurons and their central term-
inals is heterogeneous, with TRPA1 being expressed in
TRPV1-containing, peptidergic C-fibre afferents and
TRPM8 being expressed by a diverse range of Aδ- and C-
fibre afferents [36-38,41,63]. This is consistent with elec-
trophysiological evidence that putative TRPV1, TRPM8
and TRPA1 agonists target partially distinct presynaptic
inputs to subpopulations of dorsal horn neurons
[28,29,31,32]. While there is considerable evidence for a
substantial overlap in the expression of μ-a n dδ-opioid
receptors in DRG neurons [e.g. [8,21,64]] it has recently
been suggested that μ-a n dδ-opioid receptors are
expressed in distinct subpopulations of peptidergic and
non-peptidergic DRG neurons, respectively [13,14]. The
latter does not entirely match our suggestion of δ-opioid
receptor/TRPA1 co-expression, although the precise rela-
tionship between TRP ion channel and opioid receptor
expression in DRG neurons remains to be determined. It
is interesting to note that μ-a n dδ-opioid receptor con-
taining afferent pathways have been reported to convey
noxious thermal and mechanical nociception, respec-
tively [13]. In addition, TRPA1 has been reported to
respond to noxious cold, mechanical pressure, exogenous
and endogenous irritants, and has been implicated in
chronic pain states [for review see [65,66]]. While little is
known about the clinical utility of δ-opioids [67], the pre-
sent findings suggest that they may have potential in
specific pain modalities, including noxious mechanical
forces and irritants, and in chronic pain states.
Conclusions
The present results suggest that, unlike μ-opioid recep-
tors, δ-opioid receptor activation presynaptically inhibits
a specific subpopulation of excitatory glutamatergic
inputs onto dorsal horn neurons. This δ-opioid sensitive
subpopulation of inputs could potentially correlate to the
recently described afferent pathway which conveys nox-
ious mechanical sensation. In addition, our findings sug-
gest that the δ-opioid sensitive inputs convey TRPA1-like
noxious chemical sensation, although a role for other ici-
lin-sensitive TRP channels cannot be excluded. Together,
these findings suggest that δ-opioid agonists may provide
a novel analgesic target for specific pain modalities.
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